English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Overexpression of EagI potassium channels in clinical tumours

Hemmerlein, B., Weseloh, R. M., Mello de Queiroz, F., Knötgen, H., Sanchez, A., Rubio, M. E., et al. (2006). Overexpression of EagI potassium channels in clinical tumours. Molecular Cancer, 5: 41. doi:10.1186/1476-4598-5-41.

Item is

Files

show Files
hide Files
:
Hemmerlein_06.pdf (Any fulltext), 2MB
Name:
Hemmerlein_06.pdf
Description:
-
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
eDoc_access: PUBLIC
License:
-

Locators

show

Creators

show
hide
 Creators:
Hemmerlein, Bernhard, Author
Weseloh, Rüdiger M.1, Author              
Mello de Queiroz, Fernanda1, Author              
Knötgen, Hendrik, Author
Sanchez, Araceli1, Author              
Rubio, María E.1, Author              
Martin, Sabine1, Author              
Schliephacke, Tessa, Author
Jenke, Marc1, Author              
Radzun, Heinz-Joachim, Author
Stühmer, Walter1, Author              
Pardo, Luis A.1, Author              
Affiliations:
1Molecular biology of neuronal signals, Max Planck Institute of Experimental Medicine, Max Planck Society, ou_2173656              

Content

show
hide
Free keywords: A-GO-GO; K+ CHANNELS; ESCHERICHIA-COLI; MELANOMA-CELLS; BREAST-CANCER; ION CHANNELS; EXPRESSION; ETHER; CLONING; HERG
 Abstract: Background: Certain types of potassium channels (known as Eag1, KCNHO1, Kv10.1) are associated with the production of tumours in patients and in animals. We have now studied the expression pattern of the Eag1 channel in a large range of normal and tumour tissues from different collections utilising molecular biological and immunohistochemical techniques. Results: The use of reverse transcription real-time PCR and specifically generated monoclonal anti-Eag1 antibodies showed that expression of the channel is normally limited to specific areas of the brain and to restricted cell populations throughout the body. Tumour samples, however, showed a significant overexpression of the channel with high frequency (up to 80% depending on the tissue source) regardless of the detection method (staining with either one of the antibodies, or detection of Eag1 RNA). Conclusion: Inhibition of Eag1 expression in tumour cell lines reduced cell proliferation. Eag1 may therefore represent a promising target for the tailored treatment of human tumours. Furthermore, as normal cells expressing Eag1 are either protected by the blood-brain barrier or represent the terminal stage of normal differentiation, Eag1 based therapies could produce only minor side effects.

Details

show
hide
Language(s): eng - English
 Dates: 2006-10
 Publication Status: Published in print
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: Peer
 Identifiers: eDoc: 292150
ISI: 000241536800001
ISI: 000241536800001
DOI: 10.1186/1476-4598-5-41
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Molecular Cancer
  Alternative Title : Mol. Cancer
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 5 Sequence Number: 41 Start / End Page: - Identifier: ISSN: 1476-4598